Taken together, while tunicamycin was not selectively cytotoxic for FLT3ITD-expressing cells as a single compound, it exhibited a pronounced synergy with different clinically relevant FLT3 inhibitors for FLT3ITD-expressing cell lines and primary AML cells. The gene discussed is FLT3; the disease is acute myeloid leukemia.